Less Ads, More Data, More Tools Register for FREE

Pin to quick picksIQ-AI Regulatory News (IQAI)

  • There is currently no data for IQAI

Rule 8.3 - Flying Brands

3 Oct 2008 09:14

FORM 8.3 DEALINGS BY PERSONS WITH INTERESTS IN SECURITIES REPRESENTING 1% OR MORE (Rule 8.3 of the Takeover Code) 1. KEY INFORMATION \* TName of person dealing (Note 1) River and Mercantile Asset Management---------------------------------------------------------------------------------------------------------Company dealt in Flying Brands UTS---------------------------------------------------------------------------------------------------------Class of relevant security to which the Securities of the offeree company dealings being disclosed relate (Note 2)---------------------------------------------------------------------------------------------------------Date of dealing 02/10/08---------------------------------------------------------------------------------------------------------\* T 2. INTERESTS, SHORT POSITIONS AND RIGHTS TO SUBSCRIBE (a) Interests and short positions (following dealing) in the class of relevantsecurity dealt in (Note 3) \* T Long Short-------------------------------------------------------------------------------------------------------- Number (%) Number (%)--------------------------------------------------------------------------------------------------------(1) Relevant securities 2,177,558 8.59%--------------------------------------------------------------------------------------------------------(2) Derivatives (other than options)--------------------------------------------------------------------------------------------------------(3) Options and agreements to purchase/sell--------------------------------------------------------------------------------------------------------Total--------------------------------------------------------------------------------------------------------\* T (b) Interests and short positions in relevant securities of the company, otherthan the class dealt in (Note 3) \* T Class of relevant security: Long Short-------------------------------------------------------------------------------------------------------- Number (%) Number (%)--------------------------------------------------------------------------------------------------------(1) Relevant securities--------------------------------------------------------------------------------------------------------(2) Derivatives (other than options)--------------------------------------------------------------------------------------------------------(3) Options and agreements to purchase/sell--------------------------------------------------------------------------------------------------------Total--------------------------------------------------------------------------------------------------------\* T (c) Rights to subscribe (Note 3) \* TClass of relevant security: Details---------------------------------------------------------------------------------------------------------1 Ord 0.005P---------------------------------------------------------------------------------------------------------\* T 3. DEALINGS (Note 4) (a) Purchases and sales \* TPurchase/sale Number of securities Price per unit (Note 5)---------------------------------------------------------------------------------------------------------Purchase 105,000£0.45---------------------------------------------------------------------------------------------------------\* T (b) Derivatives transactions (other than options) \* TProduct name, Long/short (Note 6) Number of securities (Note 7) Price per unit (Note 5)e.g. CFD--------------------------------------------------------------------------------------------------------\* T (c) Options transactions in respect of existing securities (i) Writing, selling, purchasing or varying \* TProduct name, Writing, Number of Exercise Type, e.g. Expiry Option moneye.g. call option selling, securities to price American, date paid/received purchasing, which the option European per unit (Note varying etc. relates (Note 7) etc. 5)-------------------------------------------------------------------------------------------------------\* T (ii) Exercising \* TProduct name, e.g. call option Number of securities Exercise price per unit (Note 5)---------------------------------------------------------------------------------------------------------\* T (d) Other dealings (including new securities) (Note 4) \* TNature of transaction (Note 8) Details Price per unit (if applicable) (Note 5)---------------------------------------------------------------------------------------------------------\* T 4. OTHER INFORMATION Agreements, arrangements or understandings relating to options or derivatives \* TFull details of any agreement, arrangement or understanding between the person disclosing and any other person relating to the voting rights of any relevant securities under any option referred to on this form or relating to the voting rights or future acquisition or disposal of any relevant securities to which any derivative referred to on this form is referenced. If none, this should be stated.---------------------------------------------------------------------------------------------------------\* T Is a Supplemental Form 8 attached? (Note 9) YES/NO \* TDate of disclosure 03/10/08---------------------------------------------------------------------------------------------------------Contact name Michael Anglim---------------------------------------------------------------------------------------------------------Telephone number 020 7601 6247---------------------------------------------------------------------------------------------------------If a connected EFM, name of offeree/offeror with which connected---------------------------------------------------------------------------------------------------------If a connected EFM, state nature of connection (Note 10)---------------------------------------------------------------------------------------------------------\* T Notes The Notes on Form 8.3 can be viewed on the Takeover Panel's website atwww.thetakeoverpanel.org.uk Copyright Business Wire 2008
Date   Source Headline
18th Aug 202311:20 amRNSIB & GE HealthCare Enter into Commercial Agreement
17th Aug 20237:00 amRNSHalf-year Report
19th Jul 20237:00 amRNSImaging Biometrics Installs IB Nimble™ For MCW
13th Jul 20237:00 amRNSOrphan Drug Designation for GaM in Pediatric GBM
27th Jun 20237:00 amRNSStudies Show GaM Inhibits Pediatric Tumor Growth
23rd May 202311:02 amRNSResult of AGM
23rd May 20237:00 amRNSAGM Statement
3rd May 20234:14 pmRNSNotice of AGM
26th Apr 20237:00 amRNSFinal Results
28th Feb 20233:52 pmRNSOrphan Drug Designation Status
13th Jan 20232:05 pmRNSSecond Price Monitoring Extn
13th Jan 20232:00 pmRNSPrice Monitoring Extension
13th Jan 202311:05 amRNSSecond Price Monitoring Extn
13th Jan 202311:00 amRNSPrice Monitoring Extension
10th Jan 20237:00 amRNSLetter to Shareholders
2nd Dec 202211:11 amRNSHolding in Company
25th Oct 202211:00 amRNSPrice Monitoring Extension
30th Sep 20227:00 amRNSLetter to Shareholders
26th Sep 20227:00 amRNSIssue of Warrants to Employees
16th Aug 20224:40 pmRNSSecond Price Monitoring Extn
16th Aug 20224:35 pmRNSPrice Monitoring Extension
16th Aug 20229:28 amRNSHalf-year Report
3rd Aug 20221:01 pmRNSTR1 - Notification of Major Holdings
11th Jul 20227:00 amRNSImaging Biometrics Announces Channel Partnership
31st May 202211:05 amRNSSecond Price Monitoring Extn
31st May 202211:00 amRNSPrice Monitoring Extension
31st May 20228:00 amRNSSubmission of FDA 510(k) Application for IB Zero G
30th May 202210:47 amRNSResult of AGM
5th May 20223:00 pmRNSNotice of AGM
3rd May 20222:21 pmRNSIB Broadens Quantitative Mapping
28th Apr 20225:52 pmRNSFinal Results
9th Mar 20223:08 pmRNSIQAI’s Sponsored Phase I Clinical Trial is Open
28th Feb 202211:12 amRNSTotal Voting Rights
8th Feb 20227:00 amRNSIssue of shares to Mayo Clinic
27th Jan 20227:00 amRNSImaging Biometrics LLC - Letter to Shareholders
4th Jan 20229:27 amRNSDirector/PDMR Shareholding
17th Dec 20217:37 amRNSIQ-AI Prepares for Phase I Clinical Trial Launch
13th Dec 202110:32 amRNSDirector's Interest
11th Nov 20218:52 amRNSAgreement with St. Jude Children’s Hospital
2nd Nov 20218:19 amRNSMD ANDERSON ADOPTS IB CLINIC
28th Oct 20214:00 pmRNSLetter to Shareholders
7th Oct 20214:41 pmRNSSecond Price Monitoring Extn
7th Oct 20214:36 pmRNSPrice Monitoring Extension
7th Oct 20212:05 pmRNSSecond Price Monitoring Extn
7th Oct 20212:00 pmRNSPrice Monitoring Extension
7th Oct 202112:00 pmRNSPlacing
1st Oct 20218:17 amRNSCase Report on Clinical Value of IB Software
22nd Sep 20217:00 amRNSEU PATENT FOR DUAL-ECHO MR PERFUSION PROCESSSING
17th Sep 20217:00 amRNSIB Software Chosen for Accuracy and Automation
10th Sep 20217:00 amRNSUpdate on Phase I Clinical Trial

Due to London Stock Exchange licensing terms, we stipulate that you must be a private investor. We apologise for the inconvenience.

To access our Live RNS you must confirm you are a private investor by using the button below.